

# ContraVir Pharmaceuticals

12:15 17 Jun 2019

## Investors cheer ContraVir's positive results from a human-liver experiment using its CRV431 drug candidate

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) increased by double-digits Monday after reporting positive results from a human-liver experiment using its drug candidate CRV431.

The Edison, New Jersey-based biotech company is developing CRV431 to treat nonalcoholic steatohepatitis (NASH), commonly called "fatty liver," which causes liver inflammation and damage from a buildup of fat.

ContraVir said in a statement that CRV431 "was found to be 100% effective at preventing fibrosis induction beyond baseline levels" in the first study with human liver-slice cultures. Fibrosis, or scarring, of the liver is a hallmark symptom of NASH that results in impaired liver function.

Investors cheered the results, recently sending the company's stock up 48% to \$13.22 a share on heavy volume.

### READ: ContraVir Pharmaceuticals stock rockets on promising data for its liver treatment CRV431

"The results from this study are highly meaningful because they come from fully intact samples of human livers," said CEO Dr Robert Foster. "The closer that experimental models are to replicating what happens in the human body, the greater the likelihood that the therapeutic effects observed in the models will translate to human diseases."

ContraVir is developing CRV431 for NASH, fibrosis, and other liver diseases such as viral hepatitis and liver cancer.

A Phase 1, single ascending dose study of CRV431 was safe and well tolerated in humans. Currently, CRV431 is being administered in a 28-day multiple ascending dose study.

Worldwide liver cancer is the second-leading cause of cancer-related deaths, with as many as 750,000 deaths annually.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

### Share Information

**Code:** CTRV

**Listing:** NASDAQ

**Sector:**

**Website:** [contravir.com](http://contravir.com)

### Company Synopsis:

*ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.